the difficulty in isolating and propagating functional primary cholangiocytes is a major limitation in the study of biliary disorders and the testing of novel therapeutic agents. to overcome this problem, we have developed a platform for the differentiation of human pluripotent stem cells (hpscs) into functional cholangiocyte-like cells (clcs). We have previously reported that our 26-d protocol closely recapitulates key stages of biliary development, starting with the differentiation of hpscs into endoderm and subsequently into foregut progenitor (Fp) cells, followed by the generation of hepatoblasts (HBs), cholangiocyte progenitors (cps) expressing early biliary markers and mature clcs displaying cholangiocyte functionality. compared with alternative protocols for biliary differentiation of hpscs, our system does not require coculture with other cell types and relies on chemically defined conditions up to and including the generation of cps. a complex extracellular matrix is used for the maturation of clcs; therefore, experience in hpsc culture and 3D organoid systems may be necessary for optimal results. Finally, the capacity of our platform for generating large amounts of disease-specific functional cholangiocytes will have broad applications for cholangiopathies, in disease modeling and for screening of therapeutic compounds.
IntroDuctIon
Adult bile ducts consist of highly functional biliary epithelial cells 1 , which regulate bile homeostasis and modulate inflammatory responses. These cells are also known as cholangiocytes and represent the main cell type affected in cholangiopathies 2,3 -a diverse group of liver disorders including diseases such as primary biliary cirrhosis and primary sclerosing cholangitis. Despite the growing importance of these diseases, research in biliary physiology and the development of new therapeutics has been hampered by the lack of robust platforms for disease modeling and highthroughput drug screening 3 . Although animal models exist, their capacity for fully reproducing human pathophysiology is limited 4, 5 , and access to primary biliary tissue remains problematic, prohibiting large-scale experiments. Here, we describe a protocol for the generation of large quantities of CLCs from human hPSCs, which can be applied to model cholangiopathies in vitro and to validate the effects of therapeutic compounds 6 .
Development of the protocol
The protocol for the generation of CLCs 6 was developed by recapitulating key stages of native bile duct development (Fig. 1a) . Cholangiocytes originate from HBs, a bipotent population of embryonic liver progenitor cells 7 that can also differentiate into hepatocytes. Hepatoblasts surrounding the portal vein give rise to a monolayer of immature cholangiocyte progenitor cells (the ductal plate) 7 , which undergoes a process of 3D remodeling and maturation, resulting in functional bile ducts.
The generation of bipotent HBs was based on our established methodology for producing hPSC-derived hepatocyte-like cells 8 . To achieve biliary commitment of HBs, we used physiological cues reported to control biliary specification, such as activin A (a member of the TGF-β superfamily) 7, 9 and fibroblast growth factor (FGF) 10 (ref. 10) . Screening a variety of growth factors, we also identified a requirement for retinoic acid 6 . The combined activation of these signaling pathways was sufficient to promote differentiation of HBs into CPs expressing early biliary markers, including KRT19 and SOX9 (ref. 6) .
Maturation of native cholangiocytes happens in synchrony with 3D re-arrangement of the ductal plate into tubular structures 7 . Most of the functional properties of the biliary epithelium are associated with absorption and secretion processes, which require a polarized epithelium forming a lumen and therefore cannot be accurately reproduced by cells organized in monolayer 11, 12 . Consequently, for the final stage of our protocol promoting CP maturation to CLCs, we developed a 3D culture system based on previous studies using Matrigel and epidermal growth factor (EGF) 13, 14 that promotes spontaneous differentiation of HBs into cystic structures expressing early biliary markers such as KRT19 (refs. 13,14) . Prolonged culture of CPs under these conditions resulted in CLC organoids with a central lumen demonstrating characteristic functional properties such as γ-glutamyl transferase (GGT) activity 6 .
Applications
The mechanisms controlling development of the human biliary tree remain poorly understood. Indeed, developmental studies in humans are limited by minimal access to fetal tissue, whereas animal models fail to fully recapitulate the development of the human biliary tree or the phenotype of developmental disorders 5 . Our in vitro system could address some of these challenges, as it
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relies on a stepwise differentiation protocol that closely mimics embryonic bile duct development. Therefore, substantial numbers of cells corresponding to different embryological stages can be easily generated, enabling mechanistic large-scale studies in biliary specification or developmental disorders. Accordingly, we applied this methodology to interrogate the role of TGF-β and Notch signaling in biliary tubulogenesis, and reproduce the Alagille syndrome phenotype in vitro 6 . The same principle could be used in future studies to explore a broad spectrum of pathways that could be involved in bile duct development and pathogenesis.
CLCs also recapitulate many physiological functions of cholangiocytes in vitro, as well as their defects in the context of disease when using hPSCs derived from patients with cholangiopathies 6 . Consequently, CLCs could present an optimal platform for modeling biliary disease, validating therapeutic compounds and screening for novel treatment agents. We have already demonstrated proof of principle for the feasibility of this application by reproducing the effects of the drugs verapamil and octreotide in our culture system 6 and using patient-specific hiPSCs to identify a new application for the experimental compound VX809 in the management of cystic fibrosis cholangiopathy 6 . Importantly, the capacity of our system for generating substantial numbers of CLCs 6 , combined with its compatibility with large-scale experimental formats (24-and 48-well plates) 6 , could set the foundation for the use of patient-derived CLCs to develop high-throughput drug screening platforms for cholangiopathies in the future.
Comparison with other methods
Primary cholangiocyte isolation has been reported [15] [16] [17] . However, such methodologies are technically challenging, support only short-term growth with limited expansion and generate limited numbers of cells, all of which are not compatible with large-scale experiments [15] [16] [17] . Furthermore, primary cholangiocytes cultured in monolayer systems have not been shown to maintain their functional properties [15] [16] [17] .
Two other protocols have been described for generating biliary epithelium from hPSCs 18, 19 . The method by Dianat et al. results in cells with a transcriptional signature 6, 19 compatible with a subpopulation of cholangiocytes located in the canals of Hering, known as small cholangiocytes 20 . Therefore, this approach is optimized for studies on small cholangiocytes and complements our protocol, which is aimed toward the production of large cholangiocytes. The method by Ogawa et al. generates cholangiocyte organoids expressing mature markers and demonstrating biliary functionality; however, biliary specification is based on a coculture system with mouse OP9 cells 12 . Although a mixed culture system may recapitulate more closely the native niche of HBs/cholangiocytes, it is technically more challenging and presents several limitations. Indeed, OP9 cells are derived from bone marrow and are known to promote hematopoietic differentiation of ESCs by secreting factors such as macrophage colony-stimulating factor (M-CSF). This poses substantial limitations for mechanistic studies in biliary specification and early biliary development, as unknown secreted factors could interfere with experimental outcomes. Furthermore, the heterogeneity of the cell population in a coculture system renders -omics studies, such as genome-wide analyses, more challenging. Consequently, the platform by Ogawa et al. may be better suited for studies in which accurate reproduction of a complex cellular niche is critical, whereas our system is more optimized for mechanistic studies in biliary development and therapeutics. 
Limitations
There are two main limitations to our platform. Our system relies on a complex extracellular matrix (Matrigel). The composition of Matrigel is not fully defined, and variation in the growth factor and protein contents of each batch could affect the efficiency of the final stage of our protocol. Furthermore, the use of Matrigel could render the translation of our platform to good manufacturing practice conditions challenging and prevent in vivo applications toward cell-based therapy and regenerative medicine. Another important consideration is the maturity of the generated cells. CLC organoids express both early and mature biliary markers and maintain some fetal characteristics corresponding more accurately to a stage between fetal and fully mature bile ducts. Consequently, before modeling adult biliary disorders, CLCs should be tested for the presence of the relevant mature markers and functionality.
Experimental design
Our method describes the generation of hPSC-derived CLC organoids over a period of 26 d. Biliary differentiation is achieved through five key stages of recapitulating bile duct development (Fig. 1) . Our protocol starts with the plating of hPSCs on day 0 (d0), and we refer to the first day of differentiation as day 1. 
Starting population considerations.
We have demonstrated that this protocol is reproducible with four different hPSC lines 6 and embryonic stem (ES) cells (Fig. 2) . Variability in differentiation capacity is a common issue with hPSC lines, which may reflect the efficiency and timing of our protocol. Therefore, some minor optimization steps may be required for each hPSC line, as described in the following sections.
Preparation of hPSCs. To achieve high differentiation efficiency, the generation of a near-homogeneous DE population is critical.
For that, hPSCs must exhibit optimal morphology and minimal background differentiation. They should first be allowed to grow to near confluence (70-80%), and then they should be broken into small clumps and plated at high density, as described in the sections below ( Fig. 1b; Steps 1-9). Clump size and density have a critical role in this step. Very small clumps or single cells are not viable after the first day of differentiation, whereas large clumps differentiate only partially, maintaining the expression of pluripotency markers at their center. Low densities prevent the cells from reaching near confluence by the end of the first stage. This can have a negative impact on paracrine signaling, cell migration and cell-to-cell contact, which are critical factors for efficient formation of the foregut epithelium. A minimum of 24 h should be allowed for the hPSCs to adhere to the plate before starting differentiation; however, this period can be extended to a maximum of 48 h if the clump size is thought to be too small.
Generation of DE and FP.
Definitive endoderm differentiation is characterized by morphological changes, epithelial-mesenchymal transition (Fig. 1b) , substantial proliferation of the cells and increased death of cells that fail to differentiate. By the end of d3, the cells should be approaching confluence (Fig. 1b) and expressing Sox17 and EOMES homogeneously (>90%, Figs. 3 and 4) . Cell proliferation continues during the FP stage, and by the end of d8 the cells should be forming a confluent epithelium with cells exhibiting a characteristic rhomboidal morphology (Fig. 1b) . in a mixed population of CPs (75%), HBs (15%) and cells at intermediate stages (Fig. 4) . Consequently, although hepatic markers such as AFP can still be detected, early biliary markers such as CK19 and SOX9 should also be expressed almost homogeneously ( Figs. 2 and 3) . Poor efficiency at this stage (<75% SOX9 + cells) could result in incomplete maturation of CLC organoids in the next step. The quality and duration of the HB stage is critical to limiting HB contamination and ensuring biliary commitment.
Therefore, for resistant hPSC lines, we recommend optimizing the duration and efficiency of HB differentiation as described in the previous section (Generation of bipotent HBs) and in the Troubleshooting section.
Generation of CLC organoids. For the final stage of our protocol, CPs are dissociated into small clumps and transferred to 3D culture conditions. Density and clump size are the factors most critical to the success of this step. Very high densities do not allow adequate For resistant lines such as H9, we recommend adding forskolin (optional step), which promotes intraluminal fluid secretion and facilitates the formation of organoids with a lumen. Of note, this step starts with a heterogeneous population of cells including HBs and CPs, and thus some hepatic contamination is expected. However, cells expressing hepatic markers such as AFP fail to form organoids and usually gravitate to the bottom of the plate. By contrast, by the end of this stage CLC organoids should express biliary (CK19, CK7, SOX9; Figs. 3 and 4), but not hepatic (AFP), markers and demonstrate functional properties characteristic of biliary epithelium, such as GGT and alkaline phosphatase (ALP) activity (Fig. 5) . Importantly, we have noticed differences in differentiation efficiency with different batches of Matrigel. For resistant hPSC lines, Matrigel should be screened for batches that support organoid formation and cholangiocyte functionality.
Controls
Intrahepatic cholangiocytes are not commercially available. Therefore, we recommend the use of fresh bile duct tissue obtained from liver donors, or frozen isolated common bile duct cholangiocytes commercially available (Celprogen) as a positive control for the expression of biliary markers. ; individual data points are demonstrated; *P < 0.05, two-tailed Student's t-test; F-test was used to compare variances, P = 0.1218 (no significant difference in variance). GGT and ALP activity were assessed using commercially available kits (MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit and BCIP/NBT Color Development Substrate, respectively) according to the manufacturer's instructions. REAGENT SETUP Gelatin for coating tissue culture plates (500 ml) Dissolve 0.5 g of gelatin in 500 ml of water for embryo transfer. Heat the mixture at 56 °C until the gelatin has fully dissolved (~30 min).  crItIcal Sterilize gelatin solution using a vacuum filter/storage bottle system. Store it at room temperature (18-25 °C) for up to 1 month. Serum-containing medium for coating tissue culture plates (500 ml) Add 50 ml of FBS, 5 ml of glutamine, 5 ml of penicillin-streptomycin (pen/strep) and 3.5 µl of β-mercaptoethanol to 450 ml of Advanced DMEM/F12.  crItIcal Sterilize serum-containing medium using a vacuum filter/ storage bottle system. Mix the medium well before filtration. Store it at 4 °C for up to 1 month. Chemically defined medium-PVA (CDM-PVA) medium for maintenance of hPSCs Combine 0.5 g of PVA, 250 ml of F12 + GlutaMAX, 250 ml of IMDM, 5 ml of concentrated lipids, 20 µl of thioglycerol, 350 µl of insulin, 250 µl of transferrin and 5 ml of pen/strep. Store the solution at 4 °C for up to 1 month. Dissolve PVA in IMDM by adding 0.5 g of PVA to 50 ml of IMDM and mixing overnight at 4 °C (e.g., using a 50-ml Falcon tube on a roller).  crItIcal Sterilize CDM-PVA medium using a vacuum filter/storage bottle system. Mix the medium well before filtration. Warm it to 37 °C before use.
MaterIals

REAGENTS
• Collagenase, 500 ml Dissolve 500 mg of collagenase IV in 400 ml of Advanced DMEM/F12 combined with 100 ml of KOSR, 5 ml of l-glutamine and 3.5 µl of β-mercaptoethanol.  crItIcal Sterilize collagenase using a vacuum filter/storage bottle system. Mix it well before filtration. Store collagenase at 4 °C for up to 1 month. Warm it to 37 °C before use. Dispase, 500 ml Dissolve 500 mg of Dispase in 500 ml of DMEM/F-12.  crItIcal Sterilize dispase using a vacuum filter/storage bottle system. The number of wells is multiplied by 50 µl, which corresponds to the volume of each dome (see Step 24) and is divided by 2 to reflect the Matrigel-media ratio (50% or 1:1).  crItIcal The supplemented WE medium should be precooled to 4 °C.  crItIcal Both Matrigel and the supplemented WE medium should be kept on ice during and after the preparation of the 50% (vol/vol) solution to avoid solidification. EQUIPMENT SETUP Gelatin/serum-coated tissue culture plates Add enough gelatin solution to fully cover the surface of the plate. Indicative volumes are 6 ml for a 10-cm plate and 1 ml for each well of a 12-well plate. Coat for a minimum of 30 min at room temperature, and then aspirate the gelatin and replace it with enough volume of serum-containing medium to fully cover the surface of the plate. Indicative volumes are 6 ml for a 10-cm plate and 1 ml for each well of a 12-well plate. Store plate in an incubator at 37 °C for up to 1 week.  crItIcal Allow a minimum of 24 h at 37 °C before using the plate. Plate heater setup Clean the plate heater with trigene and 70% (vol/vol) ethanol and place it in a tissue culture hood. Set the temperature to 37 °C and place a 24-well plate on the heating surface.  crItIcal Allow a minimum of 30 min for the plate to warm up, before plating Matrigel with cells. If you are using multiple plates, these can be prewarmed in an incubator for a minimum of 30 min, with each plate placed on the plate heater immediately before plating. proceDure passaging of hpscs • tIMInG 1 d 1| Ensure that hPSC colonies are growing and maintaining their characteristic morphology 21 . We recommend using lines that have been stable in culture for at least ten passages. Change the medium daily using CDM-PVA supplemented with activin (10 ng/ml) and FGF (12 ng/ml). Proceed to the next step when the cells are 70-80% confluent.
2|
Aspirate the medium and wash the plate with Ca2 + /Mg2 + -free PBS. The volume of PBS depends on the type of plate used. Indicative minimum volumes are 6 ml for a 10-cm plate, 1-2 ml for a well of a six-well plate and 0.5 ml for a well of a 12-well plate.
3|
Aspirate the PBS and add the appropriate volume of 1:1 collagenase/dispase solution. Refer to Step 2 for indicative volumes. Incubate at 37 °C for 30-60 min until the majority of the colonies (>90%) have detached.
4|
Tilt the plate and wait for the colonies to gravitate to its lowest part, forming a loose pellet. Using a 1,000-µl pipette to harvest the cells and transfer them to a 15-ml tube containing 6 ml of CDM-PVA. 5| Allow 1-2 min for the colonies to settle to a loose pellet. Aspirate the supernatant and add 6 ml of CDM-PVA. Repeat this step twice for a total of three washes with CDM-PVA.
6|
Aspirate the supernatant and resuspend the pellet in 1 ml of CDM-PVA supplemented with activin (10 ng/ml) and bFGF (12 ng/ml).  crItIcal step Using a 1,000-µl pipette, gently break the colonies into small clumps. Clump size can affect differentiation efficiency. Aim for clumps of 50-100 cells (Fig. 1b) .
7|
Prepare new plates by washing gelatin-coated plate with PBS, as described in Step 2. Aspirate the PBS and add the appropriate volume of CDM-PVA supplemented with activin (10 ng/ml) and bFGF (12 ng/ml), as described in Step 2.
8| Add 100 µl of the cell suspension (from Step 6) to each 10-cm dish.  crItIcal step hPSCs should be plated at a density that will allow them to reach 80% confluence in 6-8 d for maintenance plates and 3-6 d for differentiation (Fig. 1b) . This is usually achieved by using a 1:6-1:10 split ratio. Adjust the volume of cell suspension added to each plate based on your split ratio. Optimal split ratios vary and need to be adjusted for each individual hPSC line depending on its growth parameters. A typical plating density for our lines is 200,000 cells per 10-cm plate for maintenance and 500,000-1,000,000 cells for differentiation.
9|
Incubate the cells at 37 °C overnight.
Differentiation of hpscs into De
• tIMInG 3 d 10| Day 1. Ensure that hPSCs have fully attached after plating. Aspirate the medium and add freshly prepared CDM-PVA supplemented with activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10 µM) and CHIR99021 (3 µM).
Incubate the cells at 37 °C overnight. ? trouBlesHootInG 11| Day 2. Replace the medium with freshly prepared CDM-PVA supplemented with activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml) and LY294002 (10 µM). Incubate the cells at 37 °C overnight.
12| Day 3.
Replace the medium with freshly prepared RPMI/B27 medium supplemented with activin A (100 ng/ml) and bFGF (80 ng/ml). Incubate the cells at 37 °C overnight. The typical morphology of the cells at the end of this stage is demonstrated in Figure 1b. A proportion of the cells can be further characterized with flow cytometry and immunofluorescence (IF) for the expression of endoderm markers such as Sox17, anticipating >90% positive cells (Figs. 3 and 4) . 
in an appropriate volume of freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml) and Rho kinase inhibitor Y-27632 (10 µm) for a final concentration of 1 × 10 6 cells/ml.  crItIcal step Y-27632 should always be freshly added and kept in the culture for a minimum of 24 h to improve cell survival. (viii) Add the appropriate volume of cell suspension to the new plates to provide a coverage of 150,000 cells/cm 2 . Ensure that this is more than the minimum volume indicated in Step 2, and supplement with freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml) if required. (ix) Incubate the cells at 37 °C overnight.
 crItIcal step The density of the cells following the split may affect the efficiency of the later steps of differentiation. It is critical to plate the cells at an appropriately high density so that the cells are almost confluent (90%) following the split. In some cases, not all the cells attach; therefore, it is critical to look at the plates and, if necessary, increase the cell number plated to achieve the right confluence. Very high densities promoting growth of cells in overlapping layers also have a negative impact on differentiation efficiency and should be avoided. (x) Day 8. Replace the medium with freshly prepared RPMI/B27 medium supplemented with activin A (50 ng/ml).
Incubate the cells at 37 °C overnight. Further characterize a proportion of the cells with IF and flow cytometry analyses for the expression of foregut markers such as GATA4 (Figs. 3 and 4) , anticipating >90% positive cells. Replace the medium daily with freshly prepared RPMI/B27 medium supplemented with FGF10 (50 ng/ml), activin A (50 ng/ml) and retinoic acid (3 µM). Monitor CP differentiation through the expression of Sox9, which should be observed in >75% of the cells by day 16 (Fig. 4) .  crItIcal step The typical morphology of the cells is demonstrated in Figure 1b . Optimal CP differentiation is necessary for efficient differentiation of later stages. ? trouBlesHootInG passaging of cps and transfer to 3D culture conditions • tIMInG 1-2 h  crItIcal Before starting this step, ensure that the Matrigel and related equipment are prepared as described in the Reagent Setup and that the plate heater and the required number of plates are prepared as described in the Equipment Setup. 17| Day 17. Wash the cells once with PBS and add the appropriate volume of cell dissociation buffer as described in Step 2.
Incubate the cells at 37 °C for 20 min.
18|
Tap the plate to facilitate detachment. The cells should detach as a monolayer or in large clumps. If no detachment can be identified after 20 min, proceed to mechanical dissociation with a pipette using a combination of horizontal, perpendicular and circular movements. We used a 1,000-µl pipette for harvesting cells from 1 well of a 12-well plate.
19|
Transfer the cells to a 15-ml tube. Gently aspirate and resuspend the cell solution 2-3 times, using a 1,000-µl pipette, to facilitate dissociation to small clumps. Step 27, differentiation of CPs into CLC organoids: 10 d
Step 28A, IF staining of CLC organoids: 2 d
Step 28B, extraction of cells from Matrigel for further analyses: 40 min
antIcIpateD results
We describe a methodology for the differentiation of hPSCs into functional CLC organoids in 26 d. The early stages of our protocol (DE, FP, HB) result in >90% cells expressing endoderm and then FP markers (Fig. 4) . However, biliary specification of HBs results in 75% CK19 + /SOX9 + CPs, which mature into a population of 75% CK7 + CLCs during the final step of our differentiation (Fig. 4) . The resulting CLC organoids should express biliary markers such as CK19 and CK7 in IF analyses (Figs. 2 and 3) . Hepatic markers (AFP, albumin) can still be detected in these stages because of the presence of a contaminating population of hepatic-lineage cells, but these should be identified only in clumps of cells without a lumen or attached to the bottom of the plate. Furthermore, CLC organoids can be validated further for additional cholangiocyte markers such as CFTR, AE2 and secretin receptor 6 , and they should demonstrate functional properties such as luminal accumulation of rhodamine-123, and GGT and ALP activity (Fig. 5) . The methods used to characterize CLC organoids (flow cytometry, IF, rhodamine-123 accumulation, GGT activity and ALP staining) have been described elsewhere 6 . Our platform promotes substantial cell expansion. Using three different hPSC lines, we observed an average yield of >50 × 10 6 CLCs per 1 × 10 6 hPSCs. Proliferation should be particularly evident during the generation of CLC organoids. 1 × 10 5 CPs should give rise to 50-100 CLC organoids with diameters ranging between 100 and 1,000 µm. However, variations in terms of the expansion potential and the differentiation efficiency of our protocol can occur. This can be attributed to inherent differences between hPSC lines and batch-to-batch variability for some of the reagents, including Matrigel. For reproducible results, the use of fresh medium and well-preserved, small-molecule, recombinant protein and Matrigel stocks is essential. coMpetInG FInancIal Interests The authors declare competing financial interests: details are available in the online version of the paper.
